• ≥50 years of age at time of consent

• MNV secondary to nAMD with IVT anti-VEGF treatment history in the study eye, defined as EITHER:

‣ Treatment naïve, i.e. no prior IVT anti-VEGF therapy OR

⁃ Previously treated with no more than 4 IVT anti-VEGF injections due to nAMD and received diagnosis of nAMD no more than 6 months prior to the Screening Visit AND documented evidence of anatomical improvement and visual stability/improvement in response to previous IVT anti-VEGF treatment, as determined by the Investigator

• Active subfoveal MNV or juxtafoveal/ extrafoveal MNV with a subfoveal component (where activity is defined as evidence of SRF, IRF, subretinal hyperreflective material, or leakage) identified by fluorescein angiography (FA) or spectral domain optical coherence tomography (SD-OCT) , in the study eye, at the Screening Visit confirmed by the Reading Center

• Demonstrated clinical response to aflibercept and functional stability in the study eye as confirmed by the Reading Center

• BCVA between 25 and 78 ETDRS letters, inclusive (20/320-20/32 Snellen equivalent) in the study eye at the Screening Visit

• CST less than or equal to 500 microns in the study eye at screening visit, confirmed by the central reading center